These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26942251)

  • 1. gestodene + ethinvlestradiol (APLEEK⁰). No place for a patch containing a third-generation progestin.
    Prescrire Int; 2016 Jan; 25(167):10. PubMed ID: 26942251
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of an ethinyl estradiol/gestodene transdermal contraceptive patch on the endometrium: a single-center, uncontrolled study.
    Merz M; Grunert J
    Womens Health (Lond); 2014 Jan; 10(1):37-43. PubMed ID: 24328597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch.
    Zhang C; Li H; Xiong X; Zhai S; Wei Y; Zhang S; Zhang Y; Xu L; Liu L
    Drug Des Devel Ther; 2017; 11():725-731. PubMed ID: 28331292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single-center, open-label, randomized, crossover study.
    Zurth C; Schuett B; Casjens M; Ludwig M; Waellnitz K
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):245-55. PubMed ID: 27136904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.
    Wiegratz I; Bassol S; Weisberg E; Mellinger U; Merz M
    Reprod Sci; 2014 Dec; 21(12):1518-25. PubMed ID: 24784719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal contraception methods: today's patches and new options on the horizon.
    Nelson AL
    Expert Opin Pharmacother; 2015 Apr; 16(6):863-73. PubMed ID: 25800084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergic contact dermatitis due to transdermal contraception patch.
    Stricker T; Sennhauser FH
    J Pediatr; 2006 Jun; 148(6):845. PubMed ID: 16769403
    [No Abstract]   [Full Text] [Related]  

  • 9. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hormonal contraceptive patch].
    Lidegaard O
    Ugeskr Laeger; 2004 Oct; 166(41):3591. PubMed ID: 15515462
    [No Abstract]   [Full Text] [Related]  

  • 11. Evra contraceptive patch: risks of thromboembolism.
    Prescrire Int; 2007 Jun; 16(89):113-4. PubMed ID: 17590909
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical experiences concerning the intramuscular contraceptive oxogestone.
    Farkas M; Szontágh FE
    Acta Eur Fertil; 1972 Mar; 3(1):37-43. PubMed ID: 4679651
    [No Abstract]   [Full Text] [Related]  

  • 13. A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women.
    Waellnitz K; Duijkers I; Klipping C; Rautenberg T; Rohde B; Zurth C
    J Obstet Gynaecol; 2016; 36(1):106-13. PubMed ID: 26421957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate.
    Winkler J; Goldammer M; Ludwig M; Rohde B; Zurth C
    Eur J Drug Metab Pharmacokinet; 2015 Dec; 40(4):389-99. PubMed ID: 24997757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acceptability and secondary effects of a new oral contraceptive containing ethinylestradiol and gestodene].
    Cremer P; Vekemans M
    Rev Med Brux; 1987 Nov; 8(9):440-6. PubMed ID: 3423522
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical study of a low-dose contraceptive--Femodene].
    Rachev E; Damianov L; Dukovski A; Katsarova M
    Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
    Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Pearl Indices in studies of hormonal contraceptives in the United States: impact of study population.
    Gerlinger C; Trussell J; Mellinger U; Merz M; Marr J; Bannemerschult R; Schellschmidt I; Endrikat J
    Contraception; 2014 Aug; 90(2):142-6. PubMed ID: 24813941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical study of transdermal contraceptive patch in Thai adolescence women.
    Piyasirisilp R; Taneepanichskul S
    J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Systemic photosensibility and contraception].
    Schmutz JL; Barbaud A; Trechot P
    Ann Dermatol Venereol; 2011; 138(4):367-8. PubMed ID: 21497270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.